Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAPGEF4 | Q8WZA2 | 3/20 | 0.42 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.38 |
| ▸ | PGK1 | P00558 | 1/20 | 0.38 |
| ▸ | PGK2 | P07205 | 1/20 | 0.38 |
| ▸ | IDH1 | O75874 | 1/20 | 0.37 |
| ▸ | XPO1 | O14980 | 1/20 | 0.36 |
| ▸ | TAS2R14 | Q9NYV8 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | KIF11 | P52732 | 1/20 | 0.33 |
| ▸ | CES2 | O00748 | 1/20 | 0.33 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.32 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.32 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.32 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.32 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.32 |
| ▸ | ADCY8 | P40145 | 1/20 | 0.31 |
| ▸ | ADCY1 | Q08828 | 1/20 | 0.31 |
| ▸ | NOS3 | P29474 | 1/20 | 0.31 |
| ▸ | NOS1 | P29475 | 1/20 | 0.31 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL130017 | 0.82 | RAPGEF4 (0.50) | RAPGEF4NOTUMPGK1PGK2IDH1 | |
| SCHEMBL19270461 | 0.82 | CES2 (0.40) | RAPGEF4XPO1MAPTCES2 | |
| SCHEMBL107119 | 0.82 | RAPGEF4 (0.56) | RAPGEF4NOTUMPGK1PGK2IDH1 | |
| SCHEMBL3684529 | 0.82 | CES2 (0.46) | RAPGEF4XPO1MAPTCES2HDAC3 | |
| Water SCHEMBL27788452 | 0.79 | CES2 (0.44) | RAPGEF4XPO1MAPTCES2HDAC3 | |
| SCHEMBL28802521 | 0.79 | CES2 (0.44) | RAPGEF4XPO1MAPTCES2HDAC3 | |
| SCHEMBL29136201 | 0.79 | CES2 (0.44) | RAPGEF4XPO1MAPTCES2HDAC3 | |
| SCHEMBL17796960 | 0.78 | POLB (0.41) | PGK1PGK2MAPT | |
| SCHEMBL13450015 | 0.76 | KIF11 (0.44) | RAPGEF4XPO1TAS2R14MAPTKIF11 | |
| SCHEMBL12086474 | 0.73 | RXRA (0.36) | CES2HDAC3HDAC1HDAC2HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021230512-A1 | BENZAZOLE DERIVATIVE, AND ORGANIC ELECTROLUMINESCENT DEVICE COMPRISING SAME | 주식회사 랩토 | 2021-11-18 | — | — | WO | disclosed |
| US-9334373-B2 | Fire retardant materials and devices including same | THE BOARD OF REGENTS OF THE NEVADA SYSTEM OF HIGHER EDUCATION ON BEHALF OF THE UNIVERSITY OF NEVADA, LAS VEGAS (US) | 2016-05-10 | — | — | US | disclosed |
| US-20110124831-A1 | SELF-ASSEMBLED OLEFIN POLYMERIZATION CATALYST | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2011-05-26 | — | — | US | disclosed |
| EP-1697343-B1 | AMINOBENZIMIDAZOLES AND BENZIMIDAZOLES AS INHIBITORS OF RESPIRATORY SYNCYTIAL VIRUS REPLICATION | TIBOTEC PHARM LTD (IE) | 2009-07-01 | — | — | EP | disclosed |
| WO-2009072643-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-06-11 | — | — | WO | disclosed |
| EP-1847263-A2 | Inhibitors against the production and release of inflammatory cytokines | Institute of Medicinal Molecular Design, Inc. (JP) | 2007-10-24 | — | — | EP | disclosed |
| EP-1844766-A2 | Inhibitors against the production and release of inflammatory cytokines | Institute of Medicinal Molecular Design, Inc. (JP) | 2007-10-17 | — | — | EP | disclosed |
| WO-2002040445-A1 | GLUCAGON ANTAGONISTS/INVERSE AGONISTS | NOVO NORDISK A/S (DK) | 2002-05-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110124831-A1 | SELF-ASSEMBLED OLEFIN POLYMERIZATION CATALYST | MLX, KCNN4, LPXN | RAPGEF4 1120/4885NOTUM 3306/4885PGK1 4545/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.